Clinical Trial Update: Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity [Phase 3]

View source ↗

Summary

Phase 3 trial update reports results for setmelanotide in pediatric patients with rare genetic obesity conditions, including Bardet-Biedl Syndrome and monogenic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bardet-biedl Syndrome
• Lepr Deficiency Obesity
• Pcsk1 Deficiency Obesity
• Pomc Deficiency Obesity

Drugs mentioned

• Setmelanotide (setmelanotide)

Snippet

Sponsor: Rhythm Pharmaceuticals, Inc. | Conditions: Bardet-Biedl Syndrome, POMC Deficiency Obesity | Phase 3 | Status: COMPLETED | Results posted: 2024-07-10